BioDlink International Co

BioDlink International Co EBIT

The EBIT of BioDlink International Co (1875.HK) as of Oct 13, 2026 is -105.64 M CNY. In the previous year, EBIT was 41.25 M CNY — a change of -356.08% (lower).

EBIT

-105.64 MCNY

YoY

-356.08%

Last updated:

In 2025, BioDlink International Co's EBIT was -105.64 M CNY, a -356.08% increase from the 41.25 M CNY EBIT recorded in the previous year.

The BioDlink International Co EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT
Date
EBIT
Jan 1, 2021
-302.53 M CNY
Jan 1, 2022
-45.71 M CNY
Jan 1, 2023
-35.56 M CNY
Jan 1, 2024
41.25 M CNY
Jan 1, 2025
-105.64 M CNY
Jan 1, 2026 (e)
18.64 M CNY
Jan 1, 2027 (e)
77.49 M CNY
Jan 1, 2028 (e)
96.78 M CNY
The BioDlink International Co EBIT history
YEAREBITYoY
est96.78 MCNY+24.90%
est77.49 MCNY+315.72%
est18.64 MCNY-117.64%
-105.64 MCNY-356.08%
41.25 MCNY-216.03%
-35.56 MCNY-22.21%
-45.71 MCNY-84.89%
-302.53 MCNY+4.80%
-288.67 MCNY-3.35%
-298.69 MCNY+25.99%
-237.07 MCNY+123.72%
-105.97 MCNY—
Access this data via the Eulerpool API

BioDlink International Co Revenue

BioDlink International Co Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2021
86.03 M CNY
-302.53 M CNY
-304.28 M CNY
Jan 1, 2022
426.87 M CNY
-45.71 M CNY
-49.92 M CNY
Jan 1, 2023
773.73 M CNY
-35.56 M CNY
-37.76 M CNY
Jan 1, 2024
1.09 B CNY
41.25 M CNY
34.76 M CNY
Jan 1, 2025
848.36 M CNY
-105.64 M CNY
-116.92 M CNY
Jan 1, 2026 (e)
594.93 M CNY
18.64 M CNY
7.62 M CNY
Jan 1, 2027 (e)
687.52 M CNY
77.49 M CNY
54.11 M CNY
Jan 1, 2028 (e)
843.06 M CNY
96.78 M CNY
69.35 M CNY

BioDlink International Co Margins

BioDlink International Co stock margins

The BioDlink International Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of BioDlink International Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for BioDlink International Co.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
37.20 %
-351.65 %
-353.68 %
Jan 1, 2022
86.82 %
-10.71 %
-11.69 %
Jan 1, 2023
74.18 %
-4.60 %
-4.88 %
Jan 1, 2024
72.09 %
3.80 %
3.20 %
Jan 1, 2025
53.41 %
-12.45 %
-13.78 %
Jan 1, 2026 (e)
53.41 %
3.13 %
1.28 %
Jan 1, 2027 (e)
53.41 %
11.27 %
7.87 %
Jan 1, 2028 (e)
53.41 %
11.48 %
8.23 %

BioDlink International Co Stock analysis

What does BioDlink International Co do? TOT BIOPHARM International Co Ltd is a global biotechnology company based in Hong Kong. It was founded in 2005 and has since become a major player in the biopharmaceutical industry. The company's goal is to contribute to the improvement of medical care through innovative research and development of biological drugs. TOT BIOPHARM's business activities include pharmaceutical development, clinical research, and production of biological drugs. It serves various sectors, including cancer, immunology, ophthalmology, and vaccines. TOT BIOPHARM is strongly committed to the development of biopharmaceuticals and aims to be a leader in this field. One important focus of TOT BIOPHARM is the research of cancer drugs. The company has several drugs in its oncology pipeline, including a treatment for lung cancer called "Ponatinib". Additionally, TOT BIOPHARM has introduced a range of immuno-oncology therapies that can be used to treat various types of cancer. In the field of immunology, TOT BIOPHARM has launched several drugs for the treatment of autoimmune diseases, including "Natalizumab" for multiple sclerosis. Another important immunotherapy developed by TOT BIOPHARM is "Eculizumab," which is used to treat two rare blood disorders. In ophthalmology, TOT BIOPHARM is developing a new drug for the treatment of wet age-related macular degeneration (AMD). The drug is being tested in a Phase III clinical trial and has the potential to become the first biopharmaceutical for the treatment of AMD. Furthermore, TOT BIOPHARM has also developed vaccines, including a vaccine against the Japanese encephalitis virus (JEV) and a vaccine against enterovirus 71 (EV71). Both vaccines have been approved in China and are in high demand. TOT BIOPHARM's business model focuses on building a pipeline of innovative biopharmaceuticals that meet the needs of patients. The company operates a comprehensive research and development infrastructure that helps discover and develop new drug candidates. TOT BIOPHARM collaborates with universities, government agencies, and other business partners to accelerate its research and development and strengthen its market position. In addition, TOT BIOPHARM has a strong presence in the Chinese market for biopharmaceuticals. The company has a state-approved clinical research facility with over 1,000 employees in China and collaborates with leading Chinese hospitals and specialty clinics. This has given TOT BIOPHARM a preferred position in the Chinese market for biopharmaceuticals, and the company aims to expand its presence in other markets worldwide. Overall, TOT BIOPHARM International Co Ltd has built an impressive portfolio of biopharmaceuticals in recent years and is expected to continue to play a significant role in the biopharmaceutical industry. With a clear focus on research and development and a growing market position in China and other countries, the company is well-positioned to expand its business activities and strengthen its presence in the global market. BioDlink International Co is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing BioDlink International Co's EBIT

BioDlink International Co's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of BioDlink International Co's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

BioDlink International Co's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in BioDlink International Co’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about BioDlink International Co stock

EBIT of BioDlink International Co is -105.64 M CNY in 2025.

EBIT of BioDlink International Co changed from 41.25 M CNY to -105.64 M CNY, representing a -356.08% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT BioDlink International Co since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's BioDlink International Co historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — BioDlink International Co

All Key Metrics — BioDlink International Co